Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

TrojanDC

Financiado

TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IMMUNOTHERAPY

The Challenge: Cancer remains one of the major challenges to modern medicine affecting one-in-three people in Europe. Available immunotherapies are effective in a limited number of patients and often lose their efficacy due to het... ver más

30/06/2024

Asgard Therapeutic...

75K€

Presupuesto del proyecto: 75K€

Líder del proyecto

ASGARD THERAPEUTICS AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-06-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-EIE-2022-SCALEUP-02-02: Women TechEU

Innovación

Cerrada hace 2 años

0% 100% 100%

1 Participantes

Asgard Therapeutics AB

75.00K€ | Lider

Proyectos interesantes

RIPECROP RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming 3M€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

EVOLVE Extracellular Vesicle Internalizing Receptors EVIRs for Ca... 2M€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

FJCI-2017-33604 Dendritic cells in Immunotherapy 50K€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 12 meses Fecha Inicio: 2023-06-02
Fecha Fin: 2024-06-30

Líder del proyecto

ASGARD THERAPEUTICS AB

TRL 4-5

Presupuesto del proyecto 75K€

Descripción del proyecto The Challenge: Cancer remains one of the major challenges to modern medicine affecting one-in-three people in Europe. Available immunotherapies are effective in a limited number of patients and often lose their efficacy due to heterogeneity and lack of tumor-antigen presentation. Despite these shortcomings, the global immune-oncology market is one of the fastest growing therapeutics markets. Large players like Merck, Pfizer, and Novartis have shown to be keen on acquisitions of high-potential technologies. There is thus an urgent need and high demand for innovative cost-effective immunotherapies consistently effective in a broader range of cancer patients. The innovation: Asgard Therapeutics is a pre-clinical start-up company developing innovative cancer immunotherapies based in in-vivo cell reprogramming. The company is led by the scientific co-founder and CEO Cristiana Pires who, together with her co-founders, pioneered direct reprogramming to induce antigen-presenting dendritic cells. Asgard raised a € 6M seed round of funding to generate proof-of-concept for its lead candidate TrojanDC, a paradigm-shifting immunotherapy that reprograms cancer cells into antigen-presenting dendritic cells, allowing the presentation of their tumor antigens to the immune system, thereby eliciting potent anti-cancer immunity. TrojanDC has the potential to overcome challenges with current immunotherapies by reinstating cancer immunogenicity. The Women TechEU grant will allow defining a clear roadmap for the IND-enabling studies and FIH clinical trials and creating a comprehensive business plan required to raise Series A funding in Q4 2023. The Impact: With strong proof-of-concept data already obtained, an exceptional team of high-performing scientists and a strong syndicate of seasoned VCs, Asgard Therapeutics is in a unique position to develop first-in-class cancer immunotherapy based in in-vivo reprogramming.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores